This is a Continuing Medical Education article, and can be found with corresponding questions on the Internet at http://www.efns.org/EFNSContinuing-Medical-Education-online.301.0.html. Certificates for correctly answering the questions will be issued by the EFNS.
EFNS Guidelines/CME ARTICLE
EFNS task force: the use of neuroimaging in the diagnosis of dementia
Article first published online: 20 AUG 2012
© 2012 The Author(s) European Journal of Neurology © 2012 EFNS
European Journal of Neurology
Volume 19, Issue 12, pages 1487–1501, December 2012
How to Cite
Filippi, M., Agosta, F., Barkhof, F., Dubois, B., Fox, N. C., Frisoni, G. B., Jack, C. R., Johannsen, P., Miller, B. L., Nestor, P. J., Scheltens, P., Sorbi, S., Teipel, S., Thompson, P. M. and Wahlund, L.-O. (2012), EFNS task force: the use of neuroimaging in the diagnosis of dementia. European Journal of Neurology, 19: 1487–1501. doi: 10.1111/j.1468-1331.2012.03859.x
- Issue published online: 17 NOV 2012
- Article first published online: 20 AUG 2012
- Manuscript Accepted: 18 JUL 2012
- Manuscript Received: 2 JUL 2012
- Alzheimer's disease;
- amyloid imaging;
- magnetic resonance imaging;
- positron emission tomography;
- single photon emission computed tomography
Background and purpose
The European Federation of the Neurological Societies (EFNS) guidelines on the use of neuroimaging in the diagnosis and management of dementia are designed to revise and expand previous EFNS recommendations for the diagnosis and management of patients with Alzheimer's disease (AD) and to provide an overview of the evidence for the use of neuroimaging techniques in non-AD dementias, as well as general recommendations that apply to all types of dementia in clinical practice.
The task force working group reviewed evidence from original research articles, meta-analyses and systematic reviews, published before April 2012. The evidence was classified, and consensus recommendations were given and graded according to the EFNS guidance regulations.
Structural imaging, which should be performed at least once in the diagnostic work-up of patients with cognitive impairment, serves to exclude other potentially treatable diseases, to recognize vascular lesions and to identify specific findings to help distinguish different forms of neurodegenerative types of dementia. Although typical cases of dementia may not benefit from routine functional imaging, these tools are recommended in those cases where diagnosis remains in doubt after clinical and structural imaging work-up and in particular clinical settings. Amyloid imaging is likely to find clinical utility in several fields, including the stratification of patients with mild cognitive impairment into those with and without underlying AD and the evaluation of atypical AD presentations.
A number of recommendations and good practice points are made to improve the diagnosis of AD and other dementias.